Information Provided By: 
Fly News Breaks for December 20, 2019
IMMU
Dec 20, 2019 | 06:20 EDT
BofA/Merrill analyst Tazeen Ahmad initiated coverage of Immunomedics with a Buy rating and $26 price target. The company recently refiled its Biologic License Application for sacituzumab govitecan after addressing manufacturing issues, and the FDA's potential acceptance in January is a "key catalyst," Ahmad tells investors in a research note. The analyst estimates risk adjusted peak sales of $687M from triple negative breast cancer in 2029.
News For IMMU From the Last 2 Days
There are no results for your query IMMU
